Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Sickle Cells Show Potential to… >
Sickle Cells Show Potential to Attack Aggressive Cancer Tumors

Published: January 9, 2013.
By Duke University Medical Center
http://www.dukemednews.org

DURHAM, N.C. – By harnessing the very qualities that make sickle cell disease a lethal blood disorder, a research team led by Duke Medicine and Jenomic, a private cancer research company in Carmel, Calif., has developed a way to deploy the misshapen red blood cells to fight cancer tumors.

Reporting in the Jan. 9, 2013, edition of the on-line journal, PLOS ONE, the researchers describe a process of exploiting sickle-shaped red blood cells to selectively target oxygen deprived cancer tumors in mice and block the blood vessels that surround them.

"Sickle cells appear to be a potent way to attack hypoxic (oxygen-starved) solid tumors, which are notable for their resistance to existing cancer chemotherapy agents and radiation," said senior author Mark W. Dewhirst, DVM, PhD, a radiation oncologist and director of Duke's Tumor Microcirculation Laboratory. "This is an exciting finding that suggests a potential new approach to fighting tumors that are currently associated with aggressive disease."

"The very qualities that make sickle cells a danger to people with the inherited genetic disorder can be turned against tumors to fight cancer," said lead author David S. Terman, M.D., head of Molecular Genetics at Jenomic. "Our approach using sickle cells is a novel strategy with broad therapeutic potential that could be directed at breast cancers, prostate cancers, and many other solid tumors that develop resistance to current therapies."

Sickle cells are typically associated with a potentially life-threatening disease in which red blood cells are deformed in the shape of a crescent moon or sickle. Unlike healthy red blood cells that flow smoothly through vessels, the sickle cells get stuck, causing blockages that are painful and damaging to tissue.

A collaborative effort between Duke researchers and scientists from Jenomic began in 2006 to explore whether sickle cells could similarly build clots in the vast networks of blood vessels that feed oxygen-starved, or hypoxic, cancer tumors, which can grow increasingly lethal as their oxygen needs escalate.

In a National Institutes of Health-funded study of mice with breast cancer, the researchers gave the animals an infusion of fluorescently dyed sickle cells and viewed them under special window chambers that provide real-time observation of processes inside the body. Within five minutes, the deformed cells began to adhere to the blood vessels surrounding the hypoxic tumors. Over 30 minutes, the cells had formed clots and began blocking the small blood vessels that fed the tumor.

Dewhirst said the sickle cells stick like Velcro to the hypoxic tumor because it produces an abundance of adhesion molecules as part of its distress from oxygen deprivation. Normal cells don't produce the adhesion molecules, so there's nothing for the sickle cells to snag onto.

"Unlike normal red blood cells, we found that sickle cells show a highly unique natural attraction to oxygen deprived tumors where they stick, cluster and plug tumor blood vessels. Once clustered within the tumor, the sickle cells deposit a toxic iron residue as they die, causing tumor cell death," Terman said.

To boost that caustic effect, the researchers added zinc compounds (zinc protoporphyrin alone or in combination with doxorubicin) to the sickle cells, which caused even greater oxidative stress in the tumor and surrounding blood vessels. This resulted in a dramatic delay in tumor growth, quadrupling the amount of time the tumors were inactive compared to tumors exposed to regular blood cells. Mice showed no acute toxicity to the sickle cell treatment.

"In contrast to drug treatments directed only to the hypoxic tumor cell, our approach uses the inherent qualities of sickle cells to induce injury to the tumor and the vascular micro-environment that feeds the tumor," Terman said.

Dewhirst and Terman said the research team would continue to conduct studies in animals before moving to human trials.


Show Reference »


Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


 
All comments are reviewed before being posted. We cannot accept messages that refer a product, or web site.If you are looking for a response to a question please use our another feedback page.
Related »

Cell 
6/12/14 
Broad Institute, MGH Researchers Chart Cellular Complexity of Brain Tumors
By Broad Institute of MIT and Harvard
Scientists from the Broad Institute and Massachusetts General Hospital (MGH) have conducted a first-of-its-kind study that characterizes the cellular diversity within glioblastoma tumors from patients. The study, which looked …
Tumor 
5/28/10 
Circulating Tumor Cells Correlate with Poorer Survival in Pancreatic Cancer Patients
By Fox Chase Cancer Center
CHICAGO, IL. (May 28, 2010)––Fox Chase Cancer Center investigators find that pancreatic cancer patients who have circulating tumor cells tend to have worse outcomes than patients without circulating tumor …
Sarcomas 
11/30/11 
Unlocking the Genetic And Molecular Mystery of Soft-tissue Sarcoma
By Joslin Diabetes Center
Scientists at Joslin Diabetes Center in Boston have uncovered important molecular and genetic keys to the development of soft-tissue sarcomas in skeletal muscle, giving researchers and clinicians additional targets …
Dyer 
8/15/11 
Childhood Eye Tumor Made Up of Hybrid Cells with Jumbled Development
By St. Jude Children's Research Hospital
A research team led by St. Jude Children's Research Hospital scientists has identified a potential new target for treatment of the childhood eye tumor retinoblastoma. Their work also settles …
Tumor 
9/27/12 
First Use in Patient of Conditionally Reprogrammed Cells Delivers Clinical Response
By Georgetown University Medical Center
WASHINGTON – Using a newly discovered cell technology, Georgetown University Medical Center researchers were able to identify an effective therapy for a patient with a rare type of lung …
Mice 
10/22/14 

Highly Effective New Anti-cancer Drug Shows Few Side Effects in Mice
By University of Chicago Medical Center
Hypoxic 
2/14/11 
New Combination Therapy for Solid Tumors?
By Journal of Clinical Investigation
Most, if not all, solid tumors contain regions that are not well oxygenated. Tumor cells in these regions, which are known as hypoxic regions, are usually resistant to the …
Cells 
11/17/11 
Molecules on Branched-polymer Surfaces Can Capture Rare Tumor Cells in Blood
By University of Illinois at Chicago
The removal of rare tumor cells circulating in the blood might be possible with the use of biomolecules bound to dendrimers, highly branched synthetic polymers, which could efficiently sift …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese Edition